Mirum Pharmaceuticals to Present at Investor Conferences in September

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company will present at the following virtual investor conferences in September.

H.C. Wainwright & Co. 22nd Annual Global Investment Conference
September 14-15, 2020
Presentation day and time: Monday, September 14, 2020 at 9:30am ET

Cantor Fitzgerald Virtual Global Healthcare Conference
September 15-17, 2020
Presentation day and time: Thursday, September 17, 2020 at 9:20am ET

A live audio webcast and archive of the presentations will be available in the Investors & Media section of the company website at ir.mirumpharma.com.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. The company has initiated a rolling NDA submission for maralixibat in the treatment of patients with cholestatic pruritus associated with ALGS and expects to complete the submission in the first quarter of 2021. Additionally, the company plans to submit a marketing authorization application to the European Medicines Agency for maralixibat in the treatment of patients with PFIC2 in the fourth quarter 2020.

The company is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy. For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005100/en/

Investor contact:
Ian Clements, Ph.D.
[email protected]

Media contact:
Erin Murphy
[email protected]

Source: Mirum Pharmaceuticals, Inc.

You May Also Be Interested In

• Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
• TP-Link Unveils World’s First Complete Wi-Fi 8 Lineup at IFA 2026 — Regional Pre-Orders to Start on September 30th
• Furuno Unveils New SOLION-100 Terminal for Iridium GMDSS